MIEL; Hugues
Patent Applications and Registrations
Patent applications and USPTO patent grants for MIEL; Hugues.The latest application filed is for "pyrimidopyrimidinones useful as wee-1 kinase inhibitors".
- MIEL; Hugues - Craigavon GB
- Miel; Hugues - Craigavon Armagh GB
| Patent | Date |
|---|---|
| Pyrimidopyrimidinones Useful As Wee-1 Kinase Inhibitors App 20220194947 - HEWITT; Peter ; et al. | 2022-06-23 |
| Pyrimidopyrimidinones useful as wee-1 kinase inhibitors Grant 11,208,413 - Hewitt , et al. December 28, 2 | 2021-12-28 |
| Pyrimidopyrimidinones Useful As Wee-1 Kinase Inhibitors App 20210128560 - HEWITT; Peter ; et al. | 2021-05-06 |
| Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors Grant 9,850,247 - Harrison , et al. December 26, 2 | 2017-12-26 |
| Pyrimidopyrimidinones Useful As Wee-1 Kinase Inhibitors App 20160318936 - Harrison; Timothy ; et al. | 2016-11-03 |
| Inhibitors of AKT activity Grant 9,221,838 - Zhang , et al. December 29, 2 | 2015-12-29 |
| Inhibitors Of Akt Activity App 20130116243 - Zhang; Lixin ; et al. | 2013-05-09 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 